Krystal Biotech Insider Grant: 5,000 Options to Director Janney

Rhea-AI Filing Summary

Krystal Biotech, Inc. (KRYS) filed a Form 4 disclosing an equity compensation grant to director Daniel Janney on 30 June 2025.

• Type of security: Non-qualified stock option (right to buy common shares).
• Quantity: 5,000 options.
• Exercise price: $137.46 per share.
• Vesting schedule: Awards vest in equal monthly installments over 12 months beginning on the grant date.
• Expiration: 30 June 2035 (10-year term).
• Post-transaction beneficial ownership: 5,000 derivative securities reported as directly held; no change in non-derivative share ownership was reported.

The filing represents a routine director compensation grant. The size—5,000 options—equates to a low single-digit percentage of average daily trading volume and an immaterial fraction of KRYS’s ~25 million shares outstanding, implying limited dilution or market impact. No open-market purchases or sales were reported.

Insights

Securities Analyst

TL;DR: Routine director option grant; negligible dilution; neutral for valuation.

The award aligns Mr. Janney’s incentives with long-term shareholder value but does not signal insider conviction through cash purchase. With only 5,000 options (<0.02% of shares outstanding), potential dilution is immaterial. Vesting over one year aids retention while providing flexibility. No insider selling occurred, so the filing carries minimal informational content for near-term price action and is best classified as neutral from a materiality standpoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JANNEY DANIEL

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$137.46	06/30/2025		A		5,000		(1)	06/30/2035	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Daniel Janney	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KRYS disclose in the 30 June 2025 Form 4?

The company reported a grant of 5,000 stock options to director Daniel Janney at an exercise price of $137.46.

Does the filing show any insider selling of KRYS shares?

No. The Form 4 only reports an option award; there were no sales or purchases of common stock.

When do the newly granted KRYS options vest and expire?

They vest in equal monthly tranches over one year and expire on 30 June 2035.

How many derivative securities does Daniel Janney own after the transaction?

The director beneficially owns 5,000 options following this grant.

Is the option grant likely to cause meaningful dilution for KRYS shareholders?

Given the small size (<0.02% of shares outstanding), the potential dilution is immaterial.